Design Expert ® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Selegiline is a monoamine oxidase B (MAO-B) inhibitor and is used in the treatment of Parkinson’s disease. The main problem associated with its oral administration is its low oral bioavailability (10%) due to its poor aqueous solubility and extensive first pass metabolism. The aim of the present research work was to develop a nanoemulsion loaded with selegiline for direct nose-to-brain delivery for the better management of Parkinson’s disease. A quality by design (QbD) approach was used in a statistical multivariate method for the preparation and optimization of nanoemulsion. In this study, four independent variables were chosen, in which two were compositions and two were process variables, while droplet size, transmittance, zeta potential and drug release were selected as response variables. The optimized formulation was assessed for efficacy in Parkinson’s disease using behavioural studies, namely forced swimming, locomotor, catalepsy, muscle coordination, akinesia and bradykinesia or pole test in Wistar rats. The observed droplet size, polydispersity index (PDI), refractive index, transmittance, zeta potential and viscosity of selegiline nanoemulsion were found to be 61.43 ± 4.10 nm, 0.203 ± 0.005, 1.30 ± 0.01, 99.80 ± 0.04%, −34 mV and 31.85 ± 0.24 mPas respectively. Surface characterization studies demonstrated a spherical shape of nanoemulsion which showed 3.7 times enhancement in drug permeation as compared to drug suspension. The results of behaviour studies showed that treatment of haloperidol induced Parkinson’s disease in rats with selegiline nanoemulsion (administered intranasally) showed significant improvement in behavioural activities in comparison to orally administered drug. These findings demonstrate that nanoemulsion could be a promising new drug delivery carrier for intranasal delivery of selegiline in the treatment of Parkinson’s disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the presence of Tween 80, a P-glycoprotein inhibitor, the efflux pump activity was reduced.”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [65]
In the citing paper
“Among surfactants, selegiline showed highest solubility in Tween 80, which was used for the preparation of the leader formulation.”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [65]
In the citing paper
“Selegiline showed highest solubility in a mixture of grape seed oil and Sefsol 218 (1:1).”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [65]
In the citing paper
“The results of behavior studies showed that treatment of haloperidol-induced Parkinson’s disease in rats with administered intranasal selegiline NEs was characterized by a remarkable improvement in behavioral activities in comparison to the oral administrations.”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [65]
In the citing paper
“The studies showed that NE was characterized by a high flux, which was very low in the case of the suspension.”
From Nanoemulsions for “Nose-to-Brain” Drug Delivery (2019) · cites this paper as [65]
Citations
Cites
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Olsson, M., Nikkhah, G., Bentlage, C., & Bjorklund, A. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-03863.1995 · Cited by 625
Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human α-Synuclein
Fleming, S. M., Salcedo, J., Fernagut, P.-O., Rockenstein, E., Masliah, E., Levine, M. S., & Chesselet, M.-F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3080-04.2004 · Cited by 474
Intranasal nanoemulsion based brain targeting drug delivery system of risperidone
Kumar, M., Misra, A., Babbar, A. K., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.03.029 · Cited by 435 · cited 2×
“Several reported studies for drugs such as ropinirole [7], rivastigmine [8], bromocriptine [9], risperidone [10], resveratrol [11], paroxetine [12] and asenapine [13] have confirmed the theory of intranasal delivery of therapeutic molecules to the brain.”
BackgroundDevelopment and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting
Fazil, M., Md, S., Haque, S., Kumar, M., Baboota, S., Sahni, J. K., & Ali, J. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.013 · Cited by 379
Self-citationDegradation of kinetically-stable o/w emulsions
Capek, I. (2004) · Advances in Colloid and Interface Science · doi:10.1016/s0001-8686(03)00115-5 · Cited by 377
Behavioral models of Parkinson's disease in rodents: A new look at an old problem
Meredith, G. E., & Kang, U. J. (2006) · Movement Disorders · doi:10.1002/mds.21010 · Cited by 250
Zhang, H., Yao, M., Morrison, R. A., & Chong, S. (2003) · Archives of Pharmacal Research · doi:10.1007/bf02976689 · Cited by 242
The influence of surfactant mixing ratio on nano-emulsion formation by the pit method
Izquierdo, P., Feng, J., Esquena, J., Tadros, T. F., Dederen, J. C., Garcia, M. J., Azemar, N., & Solans, C. (2005) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2004.10.047 · Cited by 239
Microemulsions: A Potential Drug Delivery System
Ghosh, P., & Murthy, R. (2006) · Current Drug Delivery · doi:10.2174/156720106776359168 · Cited by 231
Cited by
Nanoemulsion: Concepts, development and applications in drug delivery
Singh, Y., Meher, J. G., Raval, K., Khan, F. A., Chaurasia, M., Jain, N. K., & Chourasia, M. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.008 · Cited by 1,358
Nanoemulsions for “Nose-to-Brain” Drug Delivery
Bonferoni, M. C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., & Giunchedi, P. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020084 · Cited by 269
Jeong, S.-H., Jang, J.-H., & Lee, Y.-B. (2023) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00589-5 · Cited by 256
Gaba, B., Khan, T., Haider, M. F., Alam, T., Baboota, S., Parvez, S., & Ali, J. (2019) · BioMed Research International · doi:10.1155/2019/2382563 · Cited by 180
Self-citationIntranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders
Bahadur, S., Pardhi, D. M., Rautio, J., Rosenholm, J. M., & Pathak, K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121230 · Cited by 170
Metadata
- Authors
- Kumar, S., Ali, J., & Baboota, S.
- Affiliations
- Hamdard University (PK)
- Corresponding author
- Baboota, Sanjula
- Venue
- Nanotechnology
- Publisher
- IOP Publishing
- Published
- 2016-09-22
- Volume
- 27
- Issue
- 43
- Pages
- 435101
- ISSN
- 0957-4484 (ISSN-L)
- 1361-6528
- OpenAlex
- W2522509600
- Cited by
- 115
- References
- 51
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 21 · 2023: 13 · 2022: 12 · 2021: 14 · 2020: 16 · 2019: 12 · 2018: 8 · 2017: 5
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- publishingsupport.iopscience.iop.org/iop-standard/v1 (vor)
- iopscience.iop.org/info/page/text-and-data-mining (tdm)
- Locations
- Nanotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Indian Council of Medical Sciences (ICMR), New Delhi (45/29/2014-Nan/BMS)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- selegiline, nanoemulsions, Parkinson's disease, intranasal drug delivery, nose-to-brain delivery, quality by design, monoamine oxidase B inhibitors, oral bioavailability, behavioral assessment, drug permeation, droplet size, zeta potential
- MeSH terms
- Animals, Behavior, Animal, Emulsions, Olfactory Bulb, Parkinson Disease, Selegiline, Solubility, Rats, Wistar, Nanostructures, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design Expert ® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease. https://app.cochat.ai/papers/10.1088/0957-4484/27/43/435101
- The paper
- Kumar, S., Ali, J., & Baboota, S. (2016). Design Expert ® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease. Nanotechnology. https://doi.org/10.1088/0957-4484/27/43/435101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.